Formycon

Formycon Liabilities

The The Liabilities of Formycon (FYB.DE) as of Nov 22, 2026 is 340.39 M EUR. In the previous year, The Liabilities was 309.87 M EUR — a change of 9.85% (higher).

Liabilities

340.39 MEUR

YoY

9.85%

Last updated:

In 2025, Formycon's total liabilities amounted to 340.39 M EUR, a 9.85% difference from the 309.87 M EUR total liabilities in the previous year.

The Formycon Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2018
6.38 M EUR
Jan 1, 2019
5.34 M EUR
Jan 1, 2020
7.56 M EUR
Jan 1, 2021
14.82 M EUR
Jan 1, 2022
497.12 M EUR
Jan 1, 2023
387.61 M EUR
Jan 1, 2024
309.87 M EUR
Jan 1, 2025
340.39 M EUR
The Formycon Liabilities history
YEARLiabilitiesYoY
340.39 MEUR+9.85%
309.87 MEUR-20.06%
387.61 MEUR-22.03%
497.12 MEUR+3,253.46%
14.82 MEUR+96.00%
7.56 MEUR+41.51%
5.34 MEUR-16.28%
6.38 MEUR+20.82%
5.28 MEUR+23.03%
4.29 MEUR+88.68%
2.28 MEUR-30.28%
3.26 MEUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Formycon Stock analysis

What does Formycon do? Formycon AG is a German biotechnology company that was founded in 2010 in Martinsried near Munich. The company's history mainly began with the development of an innovative technology concept that allows for the cost-effective and efficient production of biosimilars. The market entry started in 2017 with the launch of the first proprietary biosimilar on the European market. The core business of Formycon AG is the production and distribution of biosimilars. These are biological drugs that have a similar structure and efficacy to already approved original drugs. The development of biosimilars is complex due to the elaborate manufacturing process and high-quality assurance requirements, requiring innovative ideas and technologies. Formycon AG has developed its innovative platform technology, FORMYCON® NEXT LEVEL, which allows the company to cost-effectively produce large quantities of proteins used in cancer therapy, immunotherapy, and the treatment of autoimmune diseases. Formycon AG is divided into various divisions, including research and development, production, and distribution. In research and development, new biosimilars and other innovative technologies are developed to further improve production processes. Production takes place in a dedicated biotechnological production facility in Roth near Nuremberg, where up to eight different medications can be produced simultaneously. In the distribution sector, Formycon AG collaborates with partners who market and distribute the biosimilars in different countries. The company operates internationally, with a presence in Europe, the USA, and Asia. The biosimilars produced by Formycon AG are a cost-effective alternative to the existing original drugs. The products are used in the fields of oncology, immunology, and ophthalmology, offering patients a chance to receive effective therapy at an affordable price. Successful marketing and high demand contribute to positive company development. In 2020, Formycon AG generated a revenue of 25 million euros and currently employs approximately 150 staff members. An example of a biosimilar produced by Formycon AG is the drug FYB202, which is used for the treatment of breast, ovarian, and salivary gland cancer. It is a replica of the breast cancer medication Herceptin®, developed and distributed by the Swiss company Roche. The FYB202 biosimilar has shown in clinical studies that it is similarly effective as Herceptin® but represents a more cost-effective alternative for patients. Overall, Formycon AG pursues a sustainable business model with a focus on the development of cost-effective biosimilars. The innovative technology and focus on cost-effective production enable the company to achieve a strong market presence and offer an effective alternative to conventional drugs. Formycon is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing Formycon's Liabilities

Formycon's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Formycon's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Formycon's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Formycon's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Formycon’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Formycon stock

The Liabilities of Formycon is 340.39 M EUR in 2025.

The Liabilities of Formycon changed from 309.87 M EUR to 340.39 M EUR, representing a 9.85% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities Formycon since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's Formycon historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Formycon

All Key Metrics — Formycon